SUMMIT DETAILS
The inaugural E-Cigarette Summit was held at the Royal Society, London, in November 2013. It came at a critical point in history when both public health experts and regulators were negotiating the TPD (European Tobacco Products Directive) and grappling to understand a consumer-driven product on an unprecedented growth trajectory.
Now in its 12th year in the UK and 8th year in Washington D.C., the E-Cigarette Summit has gained an unparalleled reputation as a neutral meeting point for scientists, regulators, industry, public health, and practitioners to explore the latest research on e-cigarettes and facilitate respectful debate on what remain highly controversial issues. The aim will always be to ensure that disparate views can be explored in the context of a common aim, which is to reduce smoking-related death and disease.
HYBRID ACCESS
The Summit is planned as an in-person event for speakers, but we aim to maximise the experience for all delegates, whether you are joining us in person, watching the live stream virtually or catching up later on-demand. All Summit participants will have access to the event app where they can view the Speaker slides, follow the active chat/ discussion and submit questions for the panel debates.
We will “live stream” the Summit as per the agenda (UK Time zone). Individual videos of speaker presentations and panel discussions will be added to the virtual platform within 48 hours of the live event for you to watch/re-watch later. The app will be live for 3 months after the event.
The app will allow you to:
- View presentation PPT slides
- Join in the on-line conversation with all delegates – including those that are virtual
- Participate in Polls
- Submit/answer questions and upvote questions for the panels
- Share thoughts, photos and suggestions
- Access videos of the presentations after the event for 3 months.
2024 TOPICS
SESSION 1:
Context, Evidence & Government Challenges
- Opening Keynote: Conceptualising THR and balancing clinical and population considerations
- The Tobacco & Vapes Bill
- Situating e-cigarettes for harm reduction in the wider context:
- Cochrane Review evidence: updates on e-cigarettes for quitting smoking and emerging evidence on ways to quit vaping:
- Concern about e-cigarettes, understanding the priorities – toxicology or behaviour?
- Part 2: Complex problems, clumsy solutions and the court of public opinion
- Panel Q&A: Balancing regulatory responsibilities to improve public health
SESSION 2:
Research Informing Public Health Policy
- Vaping policies: Maximising benefits and minimising unintended consequences:
- Vaping & Illicit Drugs – Promise and pitfalls:
- E-cigarettes for smoking cessation among people experiencing homelessness (Project SCeTCH):
- Understanding & addressing harm perceptions:
- Effect of flavour descriptors and packaging on adults and youth:
- Panel Q&A: Identifying effective interventions to minimise unintended consequences
SESSION 3:
Regulatory Challenges & Potential Solutions
- The role of vaping in creating a smokefree country
- UK regulations & enforcement:
- Disruptor, disaster, or distraction? Vaping and smokefree New Zealand:
- Australia’s unique nicotine regulatory framework – can light touch medicines regulation work?
- EU Regulations: Vaping, pouches & flavours:
- Panel Q&A: Worst fears & optimal outcomes
SESSION 4:
Challenges to Ending Smoking
- U.S. Kids No Longer Smoke. Why Aren’t We Celebrating?
- Influences on smoking & vaping transitions:
- When unintended consequences are the main consequences – rethinking regulation:
- Lessons from the U.S regulatory experience – where great opportunities met reality:
- Accelerating the end of smoking:
- Closing Keynote: Real people living in real communities: Are we doing enough to make a smoke-free future a reality for everyone?
- Panel Q&A: Is smoking still the main problem?
SPEAKERS
Prof Ann McNeill
Professor of Tobacco Addiction
Institute of Psychiatry, Psychology & Neuroscience, King's College London
Prof Peter Selby
Giblon Professor and Vice Chair of Research
Department of Family and Community Medicine, University of Toronto
Richard Boden
Deputy Director Tobacco and Vaping Policy and Legislation
Office for Health Improvement and Disparities, Department of Health and Social Care
Dr. Nicola Lindson
Associate Professor in the Centre for Evidence Based Medicine
University of Oxford, Oxford, United Kingdom
Prof Alan Boobis, OBE
Emeritus Professor of Toxicology & Chair - UK Committee on Toxicity
Imperial College London
Prof Sanjay Agrawal
Professor of Respiratory Science, Institute of Lung Health
University Hospitals of Leicester NHS Trust, Special Advisor on Tobacco, Royal College of Physicians
Dr Sharon Cox
Principal Research Fellow, Tobacco and Alcohol Research Group
University College London (UCL)
Dr Katie East
Research Fellow, Society for the Study of Addiction (SSA) Griffith Edwards Academic Fellow
Nicotine Research Group, King's College London
Craig Copland
Head of E-Cigarettes, Healthcare, Quality and Access Group
MHRA - The Medicines and Healthcare products Regulatory Agency
Prof Ken Warner
Avedis Donabedian Distinguished University Professor Emeritus and Dean Emeritus
School of Public Health, University of Michigan
Prof Robert Beaglehole
Emeritus Professor
University of Auckland, New Zealand & Chair ASH - Action for Smokefree 2025, NZ
If you cannot see the full list of speakers required for this page please make sure you have ordered all speakers in your custom list.
Edit Custom Order Here »
Only administrators can see this message
